Archive for ‘Pharmaceuticals’

Withings Thermo: A Medgadget Review

Withings Thermo: A Medgadget Review



There is consolation in the fact that technology is moving forward and there are companies out there that are ready to take on established players and introduce new interesting devices, even in boring fields such as at-home thermometers. Withings, now part of Nokia, offered Medgadget a chance to play with their Withings Thermo, and we liked the device very much.

thermo-fullAccording to the company, Withings Thermo sports the following features:

• 16 infrared sensors provide a highly accurate measurement
• 2-second measurement with instant color coded fever indicator
• There’s no need to touch the skin — no mess — no germs
• Temperature history, measurement reminders & health advice right on your smartphone
• Medically-approved thermometer with in-app educational information provided by Boston Children’s Hospital

All in all, the Thermo is a beautiful piece of technology. It’s a well-designed, intuitive, smartphone integrated instrument (iOS and Android) that has just one button. You click the button twice (to turn it on and then to measure the temperature), and you are all done.

In our at home tests, Withings Thermo performed very well, consistently showing temperatures within 0.2° when measured at the same spot, or at the bilateral temporal arteries, or when it was compared against the Braun Ear Thermometer. The device is slick, very intuitive, and easy to read at night even for people with poor vision.

Its front panel not only shows temperature readings, but it also functions as a touch control display, where the user can assign readings to specific family members, for storage and display of data on one’s smartphone.

thermo-2The device easily connected to the matching smartphone application, and transferred the data flawlessly during our testing.  The smartphone app (iOS version that we tested) is well designed and very intuitive, and it has some advanced features such as “Smart Fever Management” and an app called Thermia, a service provided by Boston Children’s Hospital, that suggests proper fever management including dosages of meds.


  • beautifully designed, ergonomic, precise instrument
  • no touch, kids friendly; useful at night
  • data storage and analytics attribution to individual family members on the smartphone app
  • uses two AAA batteries with an expectant battery life of up to two years



Product page: Withings Thermo…

Flashback: Withings Releases Touchless Temporal Smartphone Connected Thermometer…

Full story

CONTOUR NEXT ONE Bluetooth Connected Glucose

CONTOUR NEXT ONE Bluetooth Connected Glucose



Ascensia Diabetes Care, a company based in Basel, Switzerland, won FDA clearance to bring to the U.S. market its CONTOUR NEXT ONE blood glucometer. The device has Bluetooth wireless connectivity that allows diabetics to upload their readings to a paired app on their iOS or Android smartphones.

The CONTOUR DIABETES app provides historical charts of blood sugar levels and lets patients understand how their diet and physical activity impacts those. This works best if the patient religiously enters the details of his/or her food intake and all the activities that take place throughout the day. All the readings and entered information can be uploaded to the “cloud” and reviewed on a computer. Reports can be emailed to one’s physician or family members to make sure everyone is on the same page and helping to keep the symptoms of diabetes in check.

The device works just fine on its own without the app, displaying readings on a built-in screen. An indicator on the left side of the device turns green, yellow, or red depending on how out of normal range the last reading was. Ascensia claims this is one of the most accurate blood glucose meters on the market, achieving ±8.4% accuracy on 95% of readings when it was compared against laboratory equipment in a small trial with human subjects.

The CONTOUR NEXT ONE will be available for purchase in the U.S. early next year and the app will show up on Apple App Store and Google Play for downloading.

Via: Ascensia Diabetes Care…


Full story

siRNA gene silencing: new Trilencer- 27 kit from AMSBIO

siRNA gene silencing: new Trilencer- 27 kit from AMSBIO

siRNA gene silencing: new Trilencer- 27 kit from AMSBIO

AMSBIO has announced its new Trilencer-27 siRNA kit, that contains Dicer-Substrate duplexes, provides critical improvements over the use of traditional 21mer siRNA designs.

G200/0138Gene silencing through the use of RNAi has become a primary tool for characterizing gene involvement in disease states and interactive pathways. Offering genome-wide coverage against human, mouse and rat, the AMSBIO Trilencer-27 siRNA kit takes advantage of the natural processing by Dicer to produce 10-fold higher potency and specificity than shorter 21mer RNAi forms. Beneficially the 27mer dicer-substrate duplexes in the kit also evade the radar of the mammalian interferon response when expressed in mammalian cells and initiate strong and specific gene silencing.

Through its optimal design (3 gene specific siRNAs and 1 negative control) – Trilencer-27 siRNA uniquely delivers the dual advantages of improved efficacy (>70% gene knockdown) and minimal interferon response.

For further information about the Trilencer-27 siRNA kit please visit or contact AMSBIO on +44-1235-828200 /

Founded in 1987, AMS Biotechnology (AMSBIO) is recognised as a leading international provider of unique, innovative products & custom services for life sciences research. The AMSBIO range includes over 23,000 polyclonal & monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, & tissue DNA, RNA, protein & microarray products. Key research areas include: apoptosis, cell invasion & migration, cell signaling, DNA damage, 3D culture, electrophoresis, glycobiology, post-translational modification & stem cell biology.

Source :

Full story

Medical Students to Wear 3D Glasses

Medical Students to Wear 3D Glasses

Medical Students to Wear 3D Glasses

Welcome to BioDigital Systems

BioDigital is dedicated to using state of the art biomedical visualization systems to improve training, communication and the interpretation of medical information. From 3D animation, to virtual training environments, to systems that intuitively store and visualize scientific data, BioDigital’s products and services promise to revolutionize the way we understand medical subjects.

BioDigital has helped a wide range of healthcare clients with their medical visualization and information system needs. Please contact us for more information on our products & services.

Pharmaceutical Industry

BioDigital works with prominent members of the pharmaceutical industry to deliver clear, visual representations of their medical therapies. These visualizations are applied in a range of distribution mediums such as news broadcasts, television commercials, web sites, presentations, press kits, print media and now even mobile for on-demand use by your sales force.

Using our unique development methodology, BioDigital’s digital artists and scientists will work with you to translate complex MOAs into concise, stimulating visuals.

Samples of some of the past work done for pharmaceuticals can be viewed in the animation gallery. Please contact us today for a free quote, consultation or any questions.

Biotech Industry


BioDigital’s expertise in communicating breakthrough science through visualization enables Biotech companies to exhibit novel therapies in radical new ways. The ability to quickly demonstrate the benefits of new discoveries to regulatory agencies, investors, scientists and potential customers is an invaluable asset when bringing new therapies to market.

From research and analysis to modeling the molecular process, BioDigital’s end to end knowledge in biochemistry and digital media will result in an outstanding visual representation of your product.

Please contact us today for a free quote, consultation or any other questions about our products and services.

Medical Device Companies

BioDigital’s use of 3D technology in education and training has resulted in unparalleled new insight into the workings of medical devices within the human body. Device companies can now show physicians and patients the benefits of their device with unprecedented clarity. Utilizing the BioDigital Human Anatomy & Platform, virtual implants, interactive procedures, and custom animation are now available to device companies of any size.

Custom Device Solutions:

Virtual Surgery & Implants

Interactive Haptic Environments

3D Animation

Marketing & Conference Graphics

Procedure Guides

Predictive Outcomes

Please contact us today for a free quote, consultation or any other questions about how BioDigital can help with your medical device visualization needs.

Hospitals & Medical Schools

The demand on hospitals to deliver more complicated treatments in less time, with greater quality, requires revolutionary approaches to information system development and education. Working under the advisement of top physicians and academic centers, BioDigital has created a range of invaluable technology to meet this demand. This need for hospitals to more efficiently communicate information will continue to drive BioDigital’s cutting edge products and services.

Some of the ways BioDigital has helped hospitals improve the quality of their healthcare include:

animation for patient education

simulators for training

information system

multimedia modules

tools for patient consultations

3D reconstruction of diagnostic scans

Please contact us for more information on how BioDigital can work with your institution.

Non-Profit Organizations

3D scientific animation has provided a new powerful way for non-profit organizations to reach the public. Charities, once limited to illustration and text, have found that using visually stunning 3D animations and graphics are incredible effective in communicating their cause. Scientific subjects once too difficult to explain can now be readily understood by the general public.

During galas, on web sites, in conference exhibits, on broadcast television and printed in annual reports are a few of the many ways charities have found value in BioDigital 3D media.

BioDigital is proud to offer discounted services for non-profit organizations. Please contact us today for a free quote, consultation or any other questions.

Exercise Science

With the use of the BioDigital Human musculoskeletal system- motion, injury and orthopedic surgery can finally be visualized for understanding by the general public. From the mechanics of proper movement to sports injury to treatments options, BioDigital’s interactive software and 3D animation will revolutionize the way we understand exercise science.

Showcase: Motion Memory Golf

When Motion Memory Golf needed help explaining the subtle difference in biomechanics between good golfers and great golfers, they worked with BioDigital’s simulation experts. Using the BioDigital Human musculoskeletal models, scientifically accurate visualizations were created to emphasize that small changes in your muscle movement – can lead to big changes in your golf game.


3D animation has quickly become a mainstream component to commercials, movies and television series, but when depicting science BioDigital’s team of biologists, physicians and animators trained specifically in the field of medicine can assure accuracy at speeds and prices unmatched by standard production firms. Over the past decade, the growth of BioDigital’s vast library of 3D assets and biomedical expertise now result in high quality animation for any budget.

Whether it is traveling through the body in a way never before possible or the science behind disease, BioDigital’s visualization services will add a engrossing new dimension to entertainment productions.

Please contact us for a free quote, consultation or any other questions about how BioDigital 3D animation can become a part of your next production.

Legal Exhibits

3D biomedical animations and illustrations can have significant impact in a court of law. These visuals, created from real data or by our scientific experts, can play an influential role in personal injury, medical malpractice or class action cases. Points previously difficult to express, can now be exhibited quickly and clearly while making a last impression on judge and jury.

Whether it’s a reconstruction of diagnostic imaging data, a static 3D graphic, or an animation of a scenario, let BioDigital’s visualization services help you gain an edge during trials.

Please contact us today for a free quote, consultation or any questions about how our visualization services can be used in the court room.

Source :

Full story

First Drug Truvada to Reduce HIV Risk

First Drug Truvada to Reduce HIV Risk

People diagnosed with HIV—the human immunodeficiency virus that without treatment develops into AIDS—take antiviral medications to control the infection that attacks their immune system. Now, for the first time, adults who do not have HIV but are at risk of becoming infected can take a medication to reduce the risk of sexual transmission of the virus. The Food and Drug Administration (FDA) has approved the new use of Truvada—to be taken once daily and used in combination with safer sex practices—to reduce the risk of sexually acquired HIV-1 infection in adults who do not have HIV but are at high risk of becoming infected. (HIV-1 is the most common form of HIV.) In two large clinical trials, daily use of Truvada was shown to significantly reduce the risk of HIV infection by 42 percent in a study sponsored by the National Institutes of Health (NIH) of about 2,500 HIV-negative gay and bisexual men and transgender women, and by 75 percent in a study sponsored by the University of Washington of about 4,800 heterosexual couples in which one partner was HIV positive and the other was not. Debra Birnkrant, M.D., director of the Division of Antiviral Products at FDA, explains that Truvada works to prevent HIV from establishing itself and multiplying in the body. She notes that while this is a new approved use, Truvada is not a new product. It was approved by FDA in 2004 for use in combination with other medications to treat HIV-infected adults and children over 12 years old. “In the 80s and early 90s, HIV was viewed as a life-threatening disease; in some parts of the world it still is. Medical advances, along with the availability of close to 30 approved individual HIV drugs, have enabled us to treat it as a chronic disease most of the time,” Birnkrant says. “But it is still better to prevent HIV than to treat a life-long infection of HIV,” she says. Birnkrant stresses that Truvada is meant to be used as part of a comprehensive HIV prevention plan that includes consistent and correct condom use, risk reduction counseling, regular HIV testing, and treatment of any other sexually-transmitted infections. Truvada is not a substitute for safer sex practices, she says. back to top Person Must Be HIV Negative Truvada, produced by Gilead Sciences Inc., is a combination of two antiretroviral medications used to treat HIV—tenofovir disoproxil fumarate and emtricitabine. When Truvada is used as a treatment for HIV rather than a preventive, the patient also takes a third drug, Birnkrant says. Which of the other approved HIV drugs is added depends on the needs of the patient.

Before this medicine is prescribed, Birnkrant says there are several factors that a person and his or her health care professional must consider in weighing the risk versus the benefit: The person must be tested to ensure that he or she is HIV negative. Flu-like symptoms—such as fever or muscle aches—are a red flag because they could indicate the presence of early, acute HIV infection, even if test results are negative. There is a window of four to five weeks with some tests, and up to three months with others, in which the antibodies that indicate HIV infection do not appear in the blood. Safety concerns tied to Truvada have to do with its effect on the bones and kidneys. While effects observed in clinical trials were mild and reversible with discontinuation of the medication, people with a history of bone or kidney ailments should be regularly monitored to ensure their continued health. It is recommended that the person also be tested for hepatitis B because worsening of hepatitis B infections has been reported in those who have both HIV-1 and hepatitis B when treatment with Truvada was stopped. back to top Infection Rates Unchanged To help prescribers and other health care professionals advise uninfected people considering taking Truvada, the medicine is being approved with a Risk Evaluation and Mitigation Strategy (REMS). The goals of the REMS are to inform prescribers and potential users of Truvada of the importance of taking the medication every day, the importance of regular HIV testing and the importance of using Truvada in combination with other measures known to reduce the risk of HIV infection. As part of the REMS, a voluntary training and education plan will be made available to potential prescribers. This program includes a medication guide and safety brochure for the prospective Truvada users that would detail the risks, recommended screening tests and key information to share with a health care professional. About 1.2 million Americans have HIV. The body’s immune system is devastated by AIDS, leaving those who have it vulnerable to deadly infections. Each year, about 50,000 adults and adolescents in the U.S. are newly diagnosed with HIV. The overall rate of HIV infection has remained stable at least since 2004. “The rates of new HIV infections have not significantly changed for a long time,” says Birnkrant. “From FDA’s standpoint, this is not acceptable for a serious disease.” This article appears on FDA’s Consumer Updates page, which features the latest on all FDA-regulated products. July 16, 2012



Full story

Disposable Insulin Delivery Device Got FDA Clearance

Disposable Insulin Delivery Device Got FDA Clearance

The V-Go Disposable Insulin Delivery Device has received 510(k) clearance from the U.S. Food and Drug Administration.

The V-Go is for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin. V-Go devices will be available in a preset basal rate to deliver 20, 30, or 40 Units of insulin in one 24-hour period (0.83 U/hr, 1.25 U/hr or 1.67 U/hr, respectively) and on-demand bolus dosing in 2 Unit increments (up to 36 Units per one 24-hour time period). The V-Go offers a simple way to deliver basal-bolus therapy.

The V-Go is the first simple, fully disposable device for the delivery of basal-bolus insulin therapy for adults with diabetes. The V-Go provides a continuous preset basal rate of insulin and allows for on-demand bolus dosing around mealtimes thereby providing an alternative to taking multiple daily insulin injections.

The V-Go is engineered to simplify basal-bolus insulin therapy for the millions of people suffering from Type 2 diabetes. The V-Go is small, lightweight, and worn under the patients clothing. It measures just 2.4 x 1.3 x 0.5 inches and weighs approximately 1 ounce when filled with insulin. Patients apply a new V-Go to the skin daily for one 24-hour period. The V-Go is not electronic, making it easy to operate and use.

About Diabetes

Diabetes is a chronic and progressive disease in which the body fails to produce or properly utilize insulin, a hormone that regulates blood sugar (glucose) levels.1 High blood glucose levels can lead to serious complications, including heart disease, stroke, high blood pressure, blindness, kidney disease, amputation, and even premature death.2

Approximately 23.6 million US children and adults have diabetes, including nearly 6 million who are undiagnosed.2 Diabetes is classified as Type 1 or Type 2. The Type 2 form of the disease is most common, affecting approximately 95% of adults with diabetes.1 In Type 2 diabetes, either the body does not produce enough insulin or the body’s cells do not use insulin properly.1 In Type 1 diabetes, the body stops producing insulin altogether.1,3

To control blood glucose levels, approximately 4.5 million people in the US with Type 2 diabetes take insulin4, which is usually administered by injection. About 3 million of these insulin users have not achieved target glucose levels currently recommended by the American Diabetes Association.4,5 In addition, many people with Type 2 diabetes could benefit from insulin therapy, but refuse to start on therapy or skip taking insulin for a variety of reasons, including interference with daily activities, injection pain, and embarrassment about injecting medication around family and friends or in public.6,7 In one study, approximately 80% of Type 2 diabetes patients only required a single daily basal rate of insulin.8 Using continuous subcutaneous insulin infusion therapy for Type 2 diabetes mellitus patients may lead to improved glycemic control.


Full story

Latest Method to Produce Extraordinary Powerful Drugs

Latest Method to Produce Extraordinary Powerful Drugs

Rhodium Catalyst is worth GOOGLE times the Gold
Researchers at the University of Buffalo Promised a Chemical Catalyst is worth GOOGLE times the Gold.A rhodium-based catalyst of 1 gram can produce 10,000 grams of a pharmaceutical products.The chemical synthesis method can be used to treat various disease for which there are no medicine up to date.
Dirhodium Technologies, LLC in Buffalo has the capacity to use this latest formula to manufacture the small molecule organic compounds which can generate the new drug applications

According to David ,”1 gram rhodium-based catalyst is capable of producing 10 kilograms of a pharmaceutical product”.

Now the Pharmaceutical companies and rest of the world know the value of the medicated Chemical Catalyst.Rhodium metal costs 10 times the price of gold so its precious than Gold.

Through chemical companies pharmaceutical scientists can use in the industry for research and also for commercial purpose.Some companies do that in Clinical trails.

Demand for this catalyst has increased from grams to Kilograms which can be use to treat  cancer to central nervous system disorders, such as depression, to inflammatory and microbial diseases and medications for treating cocaine addiction.

Davies’ collaborations with scientists in partner institutions on the Buffalo Niagara Medical Campus concludes Without a catalyst, it won’t happen.


The catalyst can produce selectively as single mirror images because opposite mirror images can have different biological effects and may be harmful.

The UB research has been funded by the National Institutes of Health and the National Science Foundation, worth of $1.6 million.

The Nature paper was co-authored by James R. Manning, a graduate student in the Department of Chemistry in the UB College of Arts and Sciences.

University at Buffalo (2008, January 28). New Method Enables Design, Production Of Extremely Novel Drugs. ScienceDaily. Retrieved October 12, 2010, from­ /releases/2008/01/080123161246.htm

Full story

Scientists Develop the First Atomic View of Key Genetic Processes

Scientists Develop the First Atomic View of Key Genetic Processes

University Park, Pa. — In a landmark study to be published in the journal Nature, scientists have been able to create the first picture of genetic processes that happen inside every cell of our bodies. Using a 3-D visualization method called X-ray crystallography, Song Tan, associate professor of biochemistry and molecular biology at Penn State, has built the first-ever image of a protein interacting with the nucleosome — DNA packed tightly into space-saving bundles organized around a protein core. The research is expected to aid future investigations into diseases such as cancer.

As the genetic blueprint of life, DNA must be deciphered or “read,” even when densely packed into nucleosomes. The nucleosome is therefore a key target of genetic processes in a cell and a focus of scientific investigations into how normal and diseased cells work. Previous studies at Penn State and other research institutions led to the discovery of chromatin enzymes — proteins that act to turn specific genes on or off by binding to the nucleosome. Since the three-dimensional structure of the nucleosome was determined 13 years ago, scientists have wondered how chromatin enzymes recognize and act on the nucleosome to regulate gene expression and other processes in a cell. “We needed to visualize how these enzymes are able to read such a complicated structure as the nucleosome,” Tan said.

To tackle this problem, Ravindra D. Makde, a postdoctoral member of the research team led by Tan, grew molecular crystals of the protein RCC1 (regulator of chromosome condensation, a protein critical for proper separation of chromosomes during cell division) bound to the nucleosome, and used X-ray crystallography to determine the atomic structure of the complex. “Our results showed that the RCC1 protein binds to opposite sides of the nucleosome — similar to pedals positioned on a tricycle wheel.” The structure provides atomic details of how an enzyme can recognize both DNA and components of the protein core of the nucleosome. Unexpectedly, the structure also showed how DNA can stretch as it wraps into a nucleosome. “These findings provide the basis for understanding how RCC1 and other chromatin enzymes interact with DNA as it is packaged into chromatin in our cells,” Tan said.

The investigations were performed at the Penn State Center for Eukaryotic Gene Regulation, a multidisciplinary center focused on understanding the molecular basis for how genes are turned off and on in our bodies. “For years, the research community has been at an impasse,” said Frank Pugh, director of the center and the Willaman professor in molecular biology at Penn State. “We were limited to only speculating how cellular proteins might bind the nucleosome. Now, with this structure, we are one step closer to understanding how cells read chromatin to regulate gene expression.”

After nearly a decade of working to this goal, Tan and his team are excited to see the intricate interactions between a chromatin protein and the nucleosome. They are, however, even more enthusiastic about future prospects. “Our goal now is to determine the structures of other biologically and medically important chromatin enzymes bound to the nucleosome,” said Tan. “We anticipate such studies will explain fundamental genetic processes and provide the basis for new therapeutics against human diseases such as cancer.”

In addition to Tan and Makde, other researchers who contributed to this project include Joseph R. England, a Penn State undergraduate when he started this research and currently an medical/doctoral student at Temple University, and Hemant P. Yennawar, a senior research associate in the Department of Biochemistry and Molecular Biology at Penn State. This research was funded, in part, by the National Institutes of Health.


Related Posts Plugin for WordPress, Blogger...

Full story

Copyright © 2018 Medical Technology & Gadgets Blog All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes